Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Jul 1;31(19):2382-7.
doi: 10.1200/JCO.2012.45.2615. Epub 2013 May 20.

Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343

Kevin S Hughes  1 , Lauren A Schnaper, Jennifer R Bellon, Constance T Cirrincione, Donald A Berry, Beryl McCormick, Hyman B Muss, Barbara L Smith, Clifford A Hudis, Eric P Winer, William C Wood
Affiliations
Randomized Controlled Trial

Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343

Kevin S Hughes et al. J Clin Oncol. .

Abstract

Purpose: To determine whether there is a benefit to adjuvant radiation therapy after breast-conserving surgery and tamoxifen in women age ≥ 70 years with early-stage breast cancer.

Patients and methods: Between July 1994 and February 1999, 636 women (age ≥ 70 years) who had clinical stage I (T1N0M0 according to TNM classification) estrogen receptor (ER) -positive breast carcinoma treated by lumpectomy were randomly assigned to receive tamoxifen plus radiation therapy (TamRT; 317 women) or tamoxifen alone (Tam; 319 women). Primary end points were time to local or regional recurrence, frequency of mastectomy, breast cancer-specific survival, time to distant metastasis, and overall survival (OS).

Results: Median follow-up for treated patients is now 12.6 years. At 10 years, 98% of patients receiving TamRT (95% CI, 96% to 99%) compared with 90% of those receiving Tam (95% CI, 85% to 93%) were free from local and regional recurrences. There were no significant differences in time to mastectomy, time to distant metastasis, breast cancer-specific survival, or OS between the two groups. Ten-year OS was 67% (95% CI, 62% to 72%) and 66% (95% CI, 61% to 71%) in the TamRT and Tam groups, respectively.

Conclusion: With long-term follow-up, the previously observed small improvement in locoregional recurrence with the addition of radiation therapy remains. However, this does not translate into an advantage in OS, distant disease-free survival, or breast preservation. Depending on the value placed on local recurrence, Tam remains a reasonable option for women age ≥ 70 years with ER-positive early-stage breast cancer.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
CONSORT diagram. Tam, tamoxifen alone; TamRT, tamoxifen plus radiation therapy.
Fig 2.
Fig 2.
Time to local or regional recurrence. HR, hazard ratio; Tam, tamoxifen alone; TamRT, tamoxifen plus radiation therapy.
Fig 3.
Fig 3.
Time to subsequent mastectomy. HR, hazard ratio; Tam, tamoxifen alone; TamRT, tamoxifen plus radiation therapy.
Fig 4.
Fig 4.
Time to distant metastasis. HR, hazard ratio; Tam, tamoxifen alone; TamRT, tamoxifen plus radiation therapy.
Fig 5.
Fig 5.
Overall survival. HR, hazard ratio; Tam, tamoxifen alone; TamRT, tamoxifen plus radiation therapy.
Fig 6.
Fig 6.
Observed versus expected survival.
Fig A1.
Fig A1.
Breast cancer–specific survival. HR, hazard ratio; Tam, tamoxifen alone; TamRT, tamoxifen plus radiation therapy.
See this image and copyright information in PMC

Comment in

References

    1. Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002;20:4141–4149. - PubMed
    1. Blamey RW, Chetty U, Bates T, et al. Radiotherapy and/or tamoxifen after conserving surgery for breast cancers of excellent prognosis: BASO II trial. Eur J Cancer. 2008;6:55. suppl. - PubMed
    1. Fyles AW, McCready DR, Manchul LA, et al. Tamoxifen with or without breast irradiation in women 50 years or older with early breast cancer. N Engl J Med. 2004;351:963–970. - PubMed
    1. Pötter R, Gnant M, Kwasny W, et al. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. Int J Radiat Oncol Biol Phys. 2007;68:334–340. - PubMed
    1. Winzer KJ, Sauerbrei W, Braun M, et al. Radiation therapy and tamoxifen after breast-conserving surgery: Updated results of a 2×2 randomised clinical trial in patients with low risk of recurrence. Eur J Cancer. 2010;46:95–101. - PubMed

Publication types

MeSH terms